Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumasiran Extension Study in PH1
NCT03350451Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Feb 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
A Phase 2 trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam Pharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT03350451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350451.